NEW YORK (GenomeWeb) - TorreyPines Therapeutics and Eisai have extended an agreement to identify and validate genes that may be used as targets for Alzheimer's drug compounds, TorreyPines said yesterday.
 
The research collaboration, which the companies began in 2005, is using whole-genome family-based association screening to identify genes associated with Alzheimer's disease.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.